

Hepatitis-C Tracking Data Report

(FY2018 Appropriation Act - Public Act 107 of 2017)

September 15, 2018

Sec. 1878. By March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:

(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(b) The total cost of treatment.

(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.

(e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.



**Michigan Department of Health and Human Services
Boilerplate Report – Revised September 2018
Boilerplate Section 1878 of PA 107 of 2017**

Sec. 1878. By March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:

(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(b) The total cost of treatment.

(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.

(e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.

(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

In Fiscal Year 2016-2017, there were 2,126 individuals treated. There were 1,074 people treated through traditional Medicaid and 1,152 people were treated through the Healthy Michigan Plan¹.

(b) The total cost of treatment.

In Fiscal Year 2016-2017, a total of \$155,984,852 was spent on drugs designed to cure Chronic Hepatitis C.

(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

Approximately \$79,045,479 of this total was spent on those treated through traditional Medicaid, while \$76,939,373 was spent on those treated through the Healthy Michigan Plan.

(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment & (e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.

To calculate the cure and reinfection rates for those receiving these treatments, practitioners who treated 2,126 patients with paid claims for these drugs from October 1, 2016 through September 30, 2017 were surveyed. This population was chosen because there would be enough time for all the necessary tests to be given to determine whether the individuals were cured. Of those 2,126, the practitioners for 1,124

¹ A small population, consisting of 100 individuals, received treatment under both traditional Medicaid and Healthy Michigan Plan. These individuals are represented in both counts only in Subsection (a).

beneficiaries completed at least part of the survey, but only 561 gave complete responses. We use those 561 in the analysis below. The overall cure rate was 99.5% and the reinfection rate is 0.9%.

- Cure Rates
 - By Metavir Score
 - F4: 99.5%
 - F3: 99.1%
 - F2: 99.4%
 - F1: 100.0%
 - F0: 100.0%
 - By Genotype
 - 1a: 99.4%
 - 1b: 98.6%
 - 1 (subtype unknown or both A and B): 100.0%
 - 2: 100.0%
 - 3: 100.0%
 - 4: 100.0%
 - Other: 100.0%
 - By Medicaid Match Rate
 - Traditional Medicaid: 99.2%
 - HMP: 99.7%
 - Individuals who changed coverage between Traditional Medicaid and HMP: 100.0%
 - By Drugs Used During Treatment
 - Harvoni: 99.2%
 - Epclusa: 100.0%
 - Zepatier: 100.0%
 - Viekira Pak: 100.0%
 - Technivie: 100.0%
 - Daklinza/Sovaldi: 100.0%
 - Harvoni/Vosevi: 100.0%
 - Mavyret: 100.0%
 - Epclusa/Vosevi: 100.0%
 - Harvoni/Zepatier: 100.0%
- Reinfection Rates
 - By Metavir Score
 - F4: 0.5%
 - F3: 2.7%
 - F2: 0.6%
 - F1: 0.0%
 - F0: 0.0%
 - By Genotype
 - 1a: 0.1%
 - 1b: 1.4%

- 1 (subtype unknown or both A and B): 0.0%
- 2: 0.0%
- 3: 1.3%
- 4: 0.0%
- Other: 0.0%
- By Medicaid Match Rate
 - Traditional Medicaid: 1.5%
 - HMP: 0.3%
 - Individuals who changed coverage between Traditional Medicaid and HMP: 0.0%
- By Drugs Used During Treatment
 - Harvoni: 1.0%
 - Epclusa: 0.8%
 - Zepatier: 0.0%
 - Viekira Pak: 0.0%
 - Technivie: 0.0%
 - Daklinza/Sovaldi: 0.0%
 - Harvoni/Vosevi: 0.0%
 - Mavyret: 0.0%
 - Epclusa/Vosevi: 0.0%
 - Harvoni/Zepatier: 0.0%